Phase I results from RTOG BR-0211, a phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD 1839 (Iressa), with radiation therapy in glioblastoma multiforme (GBM) Article

Chakravarti, A, Seiferheld, W, Robbins, I et al. (2003). Phase I results from RTOG BR-0211, a phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD 1839 (Iressa), with radiation therapy in glioblastoma multiforme (GBM) . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 57(2), s329. 10.1016/s0360-3016(03)01211-2

cited authors

  • Chakravarti, A; Seiferheld, W; Robbins, I; Guha, A; Sperduto, P; Choucair, A; Brachman, D; Mehta, M

authors

publication date

  • October 1, 2003

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Cancer

Digital Object Identifier (DOI)

publisher

  • Elsevier

start page

  • s329

volume

  • 57

issue

  • 2